Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2014

Open Access 01-12-2014 | Research

The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action

Authors: Yukiko Matsumura, Yoshihito Yokoyama, Hachidai Hirakawa, Tatsuhiko Shigeto, Masayuki Futagami, Hideki Mizunuma

Published in: Molecular Pain | Issue 1/2014

Login to get access

Abstract

Background

This study aimed to evaluate the prophylactic effect of goshajinkigan (GJG) on paclitaxel (PTX)-induced neuropathy and to elucidate the mechanism of action.

Results

There was a time-dependent irreversible decrease in pain threshold in PTX group. In PTX/GJG group, pain threshold showed changes in the same level as control. Electron microscope showed that although the ganglion cells of control and PTX/GJG groups were normal, degeneration of the nucleus and swelling of the mitochondria were observed in PTX group. Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups. In TRPV4 knock-out mice, no PTX-induced hyperalgesia was observed, and there was no significant difference in pain threshold between the 3 groups.

Conclusions

These results showed that PTX induced hyperalgesia by enhancing TRPV4 expression, and suggested that GJG might alleviate hyperalgesia by preventing degeneration of the ganglion cells and suppressing TRPV4 expression.
Appendix
Available only for authorised users
Literature
1.
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21: 3194–3200. 10.1200/JCO.2003.02.153PubMedCrossRef
2.
Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997, 8: 611–614. 10.1023/A:1008207025430PubMedCrossRef
3.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24: 3187–3205. 10.1200/JCO.2006.06.4451PubMedCrossRef
4.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29: 4189–4198. 10.1200/JCO.2010.34.4614PubMedCrossRef
5.
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96: 1682–1691. 10.1093/jnci/djh323PubMedCrossRef
6.
Ito S, Tajima K, Nogawa M, Inoue N, Kyoi T, Takahashi Y, Sasagawa T, Nakamura A, Kotera T, Ueda M, Yamashita Y, Banno K: Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. J Pharmacol Exp Ther 2012, 342: 53–60. 10.1124/jpet.111.187401PubMedCrossRef
7.
Nagano H, Sanai H, Muraoka M, Takagi K: Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol 2012, 127: 172–174. 10.1016/j.ygyno.2012.06.029PubMedCrossRef
8.
Xiao W, Boroujerdi A, Bennett GJ, Luo ZD: Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007, 144: 714–720. 10.1016/j.neuroscience.2006.09.044PubMedCentralPubMedCrossRef
9.
Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, Levine JD: Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 2004, 24: 4444–4452. 10.1523/JNEUROSCI.0242-04.2004PubMedCrossRef
10.
Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ: Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010, 6: 15. 10.1186/1744-8069-6-15PubMedCentralPubMedCrossRef
11.
12.
Ferrer-Montiel A, Fernández-Carvajal A, Planells-Cases R, Fernández-Ballester G, González-Ros JM, Messeguer A, González-Muñiz R: Advances in modulating thermosensory TRP channels. Expert Opin Ther Pat 2012, 22: 999–1017. 10.1517/13543776.2012.711320PubMedCrossRef
13.
Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA: Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405: 183–187. 10.1038/35012076PubMedCrossRef
14.
Nishizawa M, Sutherland WH, Nukada H: Gosha-jinki-gan (herbal medicine) in streptozocin-induced diabetic neuropathy. J Neurol Sci 1995, 132: 177–181. 10.1016/0022-510X(95)00141-NPubMedCrossRef
15.
Suzuki Y, Goto K, Ishige A, Komatsu Y, Kamei J: Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice. Jpn J Pharmacol 1999, 79: 169–175. 10.1254/jjp.79.169PubMedCrossRef
16.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H: Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. Cancer Chemother Pharmacol 2013, 72: 1283–1290. 10.1007/s00280-013-2306-7PubMedCentralPubMedCrossRef
17.
Kato Y, Tateai Y, Ohkubo M, Saito Y, Amagai SY, Kimura YS, Iimura N, Okada M, Matsumoto A, Mano Y, Hirosawa I, Ohuchi K, Tajima M, Asahi M, Kotaki H, Yamada H: Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats. Anticancer Drugs 2014, 25: 39–43. 10.1097/CAD.0000000000000022PubMedCrossRef
18.
Nogales E, Wolf SG, Khan IA, Ludueña RF, Downing KH: Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995, 375: 424–427. 10.1038/375424a0PubMedCrossRef
19.
Flatters SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006, 122: 245–257. 10.1016/j.pain.2006.01.037PubMedCentralPubMedCrossRef
20.
Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, Levine JD: Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 2008, 28: 1046–1057. 10.1523/JNEUROSCI.4497-07.2008PubMedCrossRef
21.
Lee H, Caterina MJ: TRPV channels as thermosensory receptors in epithelial cells. Pflugers Arch 2005, 451: 160–167. 10.1007/s00424-005-1438-yPubMedCrossRef
22.
Lin AS, Qian K, Usami Y, Lin L, Itokawa H, Hsu C, Morris-Natschke SL, Lee KH: 5-Hydroxymethyl-2-furfural, a clinical trials agent for sickle cell anemia, and its mono/di-glucosides from classically processed steamed Rehmanniae Radix. J Nat Med 2008, 62: 164–167. 10.1007/s11418-007-0206-zPubMedCrossRef
23.
Satoh H: Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients. J Integr Med 2013, 11: 11–16. 10.3736/jintegrmed2013003PubMedCrossRef
24.
Xu H, Arita H, Hayashida M, Zhang L, Sekiyama H, Hanaoka K: Pain-relieving effects of processed Aconiti tuber in CCI-neuropathic rats. J Ethnopharmacol 2006, 103: 392–397. 10.1016/j.jep.2005.08.050PubMedCrossRef
25.
Niwa Y, Miyachi Y: Antioxidant action of natural health products and Chinese herbs. Inflammation 1986, 10: 79–91. 10.1007/BF00916043PubMedCrossRef
26.
Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS: Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005, 65: 8455–8460. 10.1158/0008-5472.CAN-05-1162PubMedCrossRef
27.
Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F: Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 2006, 119: 41–48. 10.1002/ijc.21685PubMedCrossRef
28.
Lyle PA, Mitsopoulos P, Suntres ZE: N-acetylcysteine modulates the cytotoxic effects of Paclitaxel. Chemotherapy 2011, 57: 298–304. 10.1159/000329510PubMedCrossRef
29.
Flatters SJ, Xiao WH, Bennett GJ: Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006, 397: 219–223. 10.1016/j.neulet.2005.12.013PubMedCentralPubMedCrossRef
30.
Materazzi S, Fusi C, Benemei S, Pedretti P, Patacchini R, Nilius B, Prenen J, Creminon C, Geppetti P, Nassini R: TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Eur J Physiol 2012, 463: 561–569. 10.1007/s00424-011-1071-xCrossRef
31.
McKemy DD, Neuhausser WM, Julius D: Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002, 416: 52–58. 10.1038/nature719PubMedCrossRef
32.
Kono T, Satomi M, Suno M, Kimura N, Yamazaki H, Furukawa H, Matsubara K: Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. Brain Behav 2012, 2: 68–73. 10.1002/brb3.34PubMedCentralPubMedCrossRef
33.
Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, Oishi R: Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer 2012, 48: 1407–1413. 10.1016/j.ejca.2011.08.009PubMedCrossRef
34.
Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, Sugiyama T: Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res 2012, 32: 2545–2550.PubMed
35.
Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T: Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study. Exp Ther Med 2012, 3: 60–65.PubMedCentralPubMed
36.
Mizuno A, Matsumoto N, Imai M, Suzuki M: Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol 2003, 285: C96-C101. 10.1152/ajpcell.00559.2002PubMedCrossRef
37.
Suzuki M, Mizuno A, Kodaira K, Imai M: Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 2003, 278: 22664–22668. 10.1074/jbc.M302561200PubMedCrossRef
38.
Hidaka T, Shima T, Nagira K, Ieki M, Nakamura T, Aono Y, Kuraishi Y, Arai T, Saito S: Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice. Eur J Pain 2009, 13: 22–27. 10.1016/j.ejpain.2008.03.003PubMedCrossRef
39.
Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H: Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 2007, 6: 1379–1386. 10.1158/1535-7163.MCT-06-0722PubMedCrossRef
Metadata
Title
The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action
Authors
Yukiko Matsumura
Yoshihito Yokoyama
Hachidai Hirakawa
Tatsuhiko Shigeto
Masayuki Futagami
Hideki Mizunuma
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2014
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-10-61

Other articles of this Issue 1/2014

Molecular Pain 1/2014 Go to the issue

Methodology

A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments

Research

Optogenetic activation of brainstem serotonergic neurons induces persistent pain sensitization

Research

Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain

Research

TRPV1 antagonist attenuates postoperative hypersensitivity by central and peripheral mechanisms

Research

Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia

Research

Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery